Surgical Experience from Four Phase III Studies (HAVEN 1-4) of Emicizumab in Persons with Haemophilia A (PwHA) With or Without FVIII Inhibitors

Emicizumab is a novel, subcutaneously (SC) administered, recombinant, humanized, bispecific monoclonal antibody approved for the prevention of bleeds in persons with hemophilia A (PwHA). Emicizumab restores the function of activated coagulation FVIII, which is deficient in PwHA, by bridging activated FIX and FX to enable effective hemostasis.

Read More

DIVERSITY trial and Dabigatran Etexilate

Research has indicated that the incidence of venous thromboembolism (VTE) in hospitalized children has increased approximately 70% over a 6-year period and is thought to affect approximately 1 in every 200 hospitalized children.

Read More